Journal of Rare Cardiovascular Diseases

Aortic stenosis (AS) is the most frequent type of valvular heart disease. Clinically, it presents as calcific and congenital AS. Calcific AS is often age dependent and affects 2–7% of people over 65 years of age. Many clinical studies proved high correlation between age and the prevalence of calcific aortic stenosis. According to todays’ knowledge, AS presents not only as simple degenerative disease of the valve, but as an active inflammatory and proliferative process. Better control and evaluation of risk factors might decelerate progression of the disease. It is necessary to increase the knowledge about risk factors and early markers of AS. Echocardiography is the method of choice in the diagnostic course and evaluation of stenosis grade and disease progression, but the role of biomarkers is becoming more and more significant among the clinical evaluation of patients and has been already mentioned in The European Society of Cardiology (ESC) guidelines on the management of valvular heart disease in patients qualified for Aortic Valve Replacement (AVR) with severe, asymptomatic AS, preserved ejection fraction and normal exercise stress test results. The natriuretic peptides level increase at the follow-up measurements is an important co-factor in decision-making. This review article analyses and summarizes the most important research and correlation between calcific aortic valve disease and the biomarkers. The potential clinical implementation of fourteen biomarkers has been reviewed. Echocardiography depends on the operator experience and imaging quality, therefore biomarkers could contribute important information to patients’ diagnosis and follow-up.

echocardiography; aortic valve replacement; calcific aortic valve disease

Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012; 33: 2451–2496.

Bonow RO, Greenland P. Population-Wide Trends in Aortic Stenosis Incidence and Outcomes. Circulation 2015;131: 969–971. 3. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997; 29: 630–634

Nkomo VT, Gardin JM, Skelton TN. Burden of valvular heart diseases: a population-based study. Lancet. 2006; 368: 1005–1011.

Ross J, Braunwald E. Aortic Stenosis. Circulation 1968; 38: 61–67 6. Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012; 125: 76–86.

Smith JG, Luk K, Schulz CA, et al. Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Extracoronary Calcium Working Group. Association of low density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA 2014; 312: 1764–1771.

Bonow R, Greenland P. Population-Wide Trends in Aortic Stenosis Incidence and Outcomes. Circulation 2015;131: 969–971.

Englberger L, Carrel TP, Doss M, et al. Clinical performance of a sutureless aortic bioprosthesis: five-year results of the 3f Enable long-term follow-up study.J Thorac Cardiovasc Surg 2014;148 (4):1681–1687.

Breitenbach I, Wimmer-Greinecker G, Bockeria LA, et al. Sutureless aortic valve replacement with the Trilogy Aortic Valve System: multicenter experience. J Thorac Cardiovasc Surg 2010;140: 878–84, 884.e1.

Phan K, Tsai YC, Niranjan N, et al. Sutureless aortic valve replacement: a systematic review and meta-analysis. Ann Cardiothorac Surg 2015; 4: 100–111.

Vanderheyden M, Goethals M, Verstreken S, et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004; 44: 2349–2354.

Kragelund C, Grønning B, Køber L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666–675.

Cimadevilla C, Cueff C, Hekimian G, et al. Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: the COFRASA-GENERAC study. Heart 2013; 99: 461–467.

McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847.

Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2302–2308.

Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005; 26: 1023–1030.

Gerber IL, Legget ME, West TM, et al. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 2005; 95: 898–901.

Iwahashi N, Nakatani S, Umemura S, et al. Usefulness of plasma B-type natriuretic peptide in the assessment of disease severity and prediction of outcome after aortic valve replacement in patients with severe aortic stenosis. J Am Soc Echocardiogr 2011; 24: 984–991.

Pedrazzini GB, Masson S, Latini R, et al. Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting inhospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 2008; 102: 749–754.

Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation:a Canadian Cardiovascular Society position statement. Can J Cardiol 2012; 28: 520–528.

Monin JL, Lancellotti P, Monchi M, et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation 2009;120: 69–75.

Clavel MA, Malouf J, Michelena HI, et al. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am Coll Cardiol 2014; 63: 2016–2025.

Weidemann F, Herrmann S, Stork S, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009;120: 577–584.

Herrmann S, Stork S, Niemann M, et al. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol 2011; 58: 402–412.

Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: 1581–1598.

Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012; 58: 1574–1581.

Chin CW, Shah AS, McAllister DA, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. European heart journal. 2014; 35 (34): 2312–2321.

Motovska Z, Odvodyova D, Karpisek M, et al. Platelet-derived chemokines, PF-4 and RANTES, are significantly increased in hemodynamically significant degenerative aortic stenosis. International Journal of Cardiology 2011,152(2): 273–275.

Cavusoglu E, Eng C, Chopra V, et al. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 2007; 27(4): 929–935.

Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253–261.

Ikeda S, Pu WT. Expression and function of microRNAs in heart disease. Curr Drug Targets 2010; 11: 913–925.

Villar AV, García R, Merino D, et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol. 2013; 167: 2875–2881.

Yndestad A, Finsen AV, Ueland T, et al. The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure. PLoS One 2012; 7: e33 038.

Finsen AV, Ueland T, Sjaastad I, et al. The Homeostatic Chemokine CCL21 Predicts Mortality in Aortic Stenosis Patients and Modulates Left Ventricular Remodeling. Frangogiannis N, ed. PLoS ONE. 2014; 9(11): e112 172.

Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36:771–778.

Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008; 14 (9): 739–745.

Mizia-Stec K, Lasota B, Mizia M, et al. Copeptin constitutes a novel biomarker of degenerative aortic stenosis. Heart Vessels 2013: 28: 613–619.

Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic follow-up study. Am J Epidemiol 1995; 141(7):637–644.

Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med 1999; 131(1): 7–13.

Demir B, Caglar IM, Ugurlucan M, et al. The relationship between severity of calcific aortic stenosis and serum uric acid levels. Angiology 2012; 63: 603–608

Wang, T.J, Nam, B.-H, Wilson, P.W.F et al, Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002; 22: 1662–1667.

Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 10; 97(5): 425–428.

Imai K, Okura H, Kume T, et al. C-reactive protein predicts severity, progression, and prognosis of asymptomatic aortic valve stenosis. Am Heart J 2008; 156: 713–718.

Sánchez PL, Santos JL, Kaski JC, et al. Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol 2006; 97: 90–93.

Jeevanantham V, Singh N, Izuora K, et al. Correlation of high sensitivity C-reactive protein and calcific aortic valve disease. Mayo Clin Proc2007; 82: 171–174.

Blackshear JL, Wysokinska EM, Safford RE, et al. Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study). Am J Cardiol 2013; 111: 374–381.

Lai WK, Kan MY. Homocysteine-Induced Endothelial Dysfunction. Ann Nutr Metab 2015; 67(1): 1–12.

Novaro GM, Aronow HD, Mayer-Sabik E.Plasma homocysteine and calcific aortic valve disease. Heart 2004; 90: 802–803.

Thompson SG, Kienast J, Pyke SD, et al. Factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–641.

Gunduz H, Arine H, Tamer A, et al. The relationship between homomcysteine and calcific aortic valve stenosis. Cardiology. 2005; 103: 207–211.

Glader CA, Birgander LS, Söderberg S, et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J 2003;24: 198–208.

Kochtebane N, Alzahrani AMM, Bartegi A. Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. Biochemistry Research International 2014; vol 2014; article ID 658 643, 5 pages

Mills WR, Einstadter D, Finkelhor RS. Relation of calcium-phosphorus product to the severity of aortic stenosis in patients with normal renal function. Am J Cardiol 2004; 94: 1196–1198.

Linefsky JP, O’Brien KD, Katz R, et al. Association of Serum Phosphate Levels with Aortic Valve Sclerosis and Annular Calcification: the Cardiovascular Health Study. Journal of the American College of Cardiology 2011; 58(3): 291–297.

Akat K, Kaden J, Schmitz F, et al. Calcium metabolism in adults with severe aortic valve stenosis and preserved renal function. Am J Cardiol 2010; 105: 862–864.